Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price rule
ONCY•Nasdaq notice and compliance window
Oncolytics Biotech received a Nasdaq notice for failing the $1 minimum bid price rule after ONCY closed below $1 for 30 straight sessions.
Shares remain listed on the Nasdaq Capital Market while the company seeks to regain compliance.
Nasdaq set a 180-day cure window ending Jan. 19, 2027; compliance requires a closing bid of at least $1 for 10 consecutive sessions.
Failure to cure could trigger delisting risk; a second 180-day extension may be available if other listing standards are met.
